<DOC>
	<DOCNO>NCT01449812</DOCNO>
	<brief_summary>The purpose booster study evaluate immune persistence healthy Chinese subject prim study NCT01086423 GSK Biologicals ' Infanrix-IPV+Hib™ ( DTPa-IPV/Hib ) vaccine . The study also evaluate safety immune response subject booster dose Infanrix-Hib™ ( DTPa/Hib ) Poliorix™ ( IPV ) vaccine . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT01086423 ) .</brief_summary>
	<brief_title>Immunogenicity Safety Study Booster Dose GSK Biologicals ' IPV ( Poliorix™ ) DTPa/Hib ( Infanrix+Hib™ ) Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child , include , 18 24 month age time booster vaccination . Subjects complete full threedose primary vaccination course study NCT01086423 . Subjects investigator believe parent ( ) / Legally Acceptable Representative ( ) LAR ( ) comply requirement protocol Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care Use investigational nonregistered product study vaccine ( ) within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior booster vaccination , plan administration study period . Participation another clinical study within three month prior enrolment present booster study time present booster study , subject expose investigational noninvestigational product . Evidence previous diphtheria , tetanus , pertussis , poliomyelitis Haemophilus influenzae type b , vaccination disease since conclusion visit primary study NCT01086423 . Serious chronic illness . Administration immunoglobulins and/or blood product within 90 day precede booster dose study vaccine plan administration study period . Occurrence follow adverse event previous administration DTP vaccine . Encephalopathy Temperature ≥ 40.0°C ( axillary temperature ) within 48 hour vaccination , due another identifiable cause . Collapse shocklike state within 48 hour vaccination . Persistent , inconsolable cry occur within 48 hour vaccination last ≥ 3 hour . Seizures without fever occur within 3 day vaccination . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>booster vaccination</keyword>
	<keyword>combination vaccine</keyword>
</DOC>